SCHEMBL8280464

SCHEMBL8280464

C=C(O)Cc1cccc2c(=O)c3ccc(C)c(C)c3oc12

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.79
STING1 Q86WV6 1/20 0.79
KDM4E B2RXH2 1/20 0.47
MCL1 Q07820 1/20 0.41
PON1 P27169 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NQO1 P15559 1/20 0.41
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ATP1A1 P05023 1/20 0.38
ATP1B1 P05026 1/20 0.38
ATP1A3 P13637 1/20 0.38
ATP1B2 P14415 1/20 0.38
ATP1A2 P50993 1/20 0.38
ATP1B3 P54709 1/20 0.38
FXYD2 P54710 1/20 0.38
ATP1A4 Q13733 1/20 0.38
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vadimezan SCHEMBL29356696 0.88 STING1 (1.00) GLASTING1KDM4EMCL1PON1
Vadimezan SCHEMBL29363732 0.88 STING1 (1.00) GLASTING1KDM4EMCL1PON1
Vadimezan SCHEMBL111183 0.88 STING1 (1.00) GLASTING1KDM4EMCL1PON1
Vadimezan SCHEMBL4282923 0.87 STING1 (0.97) GLASTING1KDM4EMCL1PON1
Vadimezan SCHEMBL4282930 0.87 STING1 (0.97) GLASTING1KDM4EMCL1PON1
SCHEMBL13025119 0.85 GLA (0.81) GLASTING1KDM4EMCL1PON1
SCHEMBL23900884 0.85 GLA (0.75) GLASTING1KDM4EMCL1PON1
SCHEMBL12677568 0.85 GLA (0.75) GLASTING1KDM4EMCL1PON1
SCHEMBL19209663 0.84 GLA (0.79) GLASTING1KDM4EMCL1PON1
SCHEMBL20845573 0.84 GLA (0.79) GLASTING1KDM4EMCL1PON1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216497-A1 Ferritin Proteins SANOFI (FR) 2024-07-04 US disclosed
US-11904009-B2 Ferritin proteins SANOFI (FR) 2024-02-20 US disclosed
US-20230277619-A1 ANTIGENIC EPSTEIN BARR VIRUS POLYPEPTIDES SANOFI (FR) 2023-09-07 US disclosed
US-20120129895-A1 METHODS OF TREATMENT NOVARTIS AG (CH) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216497-A1 Ferritin Proteins FTH1, TFRC, SLC40A1 GLA 3085/4885STING1 270/4885KDM4E 4549/4885
US-11904009-B2 Ferritin proteins FTH1, TFRC, SLC40A1 GLA 3085/4885STING1 270/4885KDM4E 4549/4885
US-20230277619-A1 ANTIGENIC EPSTEIN BARR VIRUS POLYPEPTIDES EBNA1BP2, FTH1, CD2BP2 GLA 1611/4885STING1 693/4885KDM4E 3054/4885
US-20120129895-A1 METHODS OF TREATMENT BIRC5, BIRC3, XIAP GLA 826/4885STING1 2759/4885KDM4E 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.